Skip to main content

Blueteq High Cost Drug System

The Blueteq High Cost Drugs (HCD) system will be rolled out across NHS Wales from 1 April 2023. The HCD system will allow health boards to monitor the prescribing of high-cost medicines and manage the ever-increasing complexities associated with their use.

The Blueteq HCD system improves governance, results in faster access for patients and ensures that medicines are prescribed in accordance with health technology appraisal guidance issued by the All Wales Medicines Strategy Group (AWMSG) and the National Institute for Health and Care Excellence (NICE).

The Blueteq software offers NHS Wales a standardised process with opportunity to record multiple datasets (such as baseline demographics, clinical outcomes, patient characteristics) whilst reducing variance.

The roll-out of the Blueteq HCD system will be managed by the All Wales Blueteq Steering Group, chaired by a Chief Pharmacist and have Project Management support provided by AWTTC.

Implementation will be staged and in accordance with the priorities set out by the steering group. The initial phase will include medicines recommended for use by NICE and AWMSG which may or may not have an associated commercial arrangement.


What is the Blueteq high-cost drugs (HCD) system?

  • Blueteq is a web-based software system used widely throughout NHS England for the approval and management of high cost medicines across a range of healthcare conditions.
  • Improves governance to ensure compliance with commissioned NICE and AWMSG appraisals.
  • User-friendly tick box forms, enables instant approval for clinicians.
  • Blueteq can provide a full range of reports to clinical services to help with service development and workforce planning.

More information is available at

Follow AWTTC: